Galectin Therapeutics Inc. (NASDAQ:GALT) has been given a $2.00 target price by stock analysts at FBR & Co in a research note issued to investors on Monday. The firm presently has a a “hold” rating on the stock. FBR & Co’s target price would indicate a potential upside of 92.31% from the stock’s previous close.

GALT has been the subject of a number of other research reports. HC Wainwright lowered shares of Galectin Therapeutics from a “buy” rating to a “neutral” rating and cut their target price for the stock from $8.00 to $1.50 in a research report on Thursday, September 29th. Roth Capital reiterated a “sell” rating and set a $0.75 target price (down previously from $3.00) on shares of Galectin Therapeutics in a research report on Wednesday, September 28th. Finally, Zacks Investment Research downgraded shares of Galectin Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, October 3rd.

Galectin Therapeutics (NASDAQ:GALT) opened at 1.04 on Monday. The firm’s market capitalization is $30.45 million. Galectin Therapeutics has a 12 month low of $0.49 and a 12 month high of $3.05. The stock has a 50 day moving average of $0.96 and a 200 day moving average of $1.46.

Several large investors have recently made changes to their positions in the company. KCG Holdings Inc. purchased a new stake in shares of Galectin Therapeutics during the third quarter worth about $114,000. BlackRock Fund Advisors increased its stake in shares of Galectin Therapeutics by 33.8% in the second quarter. BlackRock Fund Advisors now owns 78,955 shares of the company’s stock worth $116,000 after buying an additional 19,967 shares in the last quarter. Benchmark Capital Advisors increased its stake in shares of Galectin Therapeutics by 98.3% in the third quarter. Benchmark Capital Advisors now owns 118,200 shares of the company’s stock worth $134,000 after buying an additional 58,600 shares in the last quarter. Courage Capital Management LLC bought a new stake in shares of Galectin Therapeutics during the third quarter worth $147,000. Finally, Advisor Group Inc. increased its stake in shares of Galectin Therapeutics by 3.8% in the third quarter. Advisor Group Inc. now owns 413,125 shares of the company’s stock worth $467,000 after buying an additional 15,200 shares in the last quarter. 11.32% of the stock is currently owned by hedge funds and other institutional investors.

Galectin Therapeutics Company Profile

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions.

5 Day Chart for NASDAQ:GALT

Receive News & Stock Ratings for Galectin Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics Inc. and related stocks with our FREE daily email newsletter.